Skip to main content

Advertisement

SpringerLink
Log in

Predicting responses to chemotherapy in breast cancer: from bench to bedside

  • Special Feature
  • Breast cancer research from bench to bedside
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Recent progress in biotechnology, notably microarray analyses, makes it possible to examine the genome-based characteristics of tumors with different prognoses and predict responses to chemotherapy. Furthermore, pharmacogenomic techniques are expected to predict the optimal regimen for individual patients that will provide high benefits with reduced toxicity. Some predictive or prognostic tests for breast cancer are now moving from bench to bedside.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclassed with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869–74.

    Article  CAS  PubMed  Google Scholar 

  2. Nielsen TO, Hsu FD, Jensen K, Maggie K, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.

    Article  CAS  PubMed  Google Scholar 

  3. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27(8):1168–76.

    Article  CAS  PubMed  Google Scholar 

  4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.

    Article  CAS  PubMed  Google Scholar 

  5. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7.

    Article  PubMed  Google Scholar 

  6. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13(5):477–93.

    Article  PubMed  Google Scholar 

  7. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. N Engl J Med. 2002;415:530–6.

    Google Scholar 

  8. http://www.eortc.be/services/unit/mindact/MINDACT_websiteii.asp.

  9. Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009: Feb 13 [Epub ahead of print]

  10. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.

    Article  CAS  PubMed  Google Scholar 

  11. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

    Article  CAS  PubMed  Google Scholar 

  12. http://www.cancer.gov/clinicaltrials/digestpage/TAILORx.

  13. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.

    Article  CAS  PubMed  Google Scholar 

  14. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23(29):7265–77.

    Article  CAS  PubMed  Google Scholar 

  15. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node-negative, estrogen receptor-positive breast cancer. In: Proceedings of ASCO. 2005 (Abstract #510).

  16. Akashi-Tanaka S, Shimizu C, Ando M, Shibata T, Katsumata N, Kouno T, et al. 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast. 2009 Apr 30 [Epub ahead of print]

  17. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676–85.

    Article  CAS  PubMed  Google Scholar 

  18. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer. 2006;94(2):247–52.

    Article  CAS  PubMed  Google Scholar 

  19. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):1789–96.

    Article  CAS  PubMed  Google Scholar 

  20. Shimizu C, Tamura K, Koizumi F, Aogi K, Kinoshita T, Fujiwara Y. Immunoglobulin G fragment C gamma receptor (FCGR) polymorphism and efficacy of single -agent trsastuzumab in patients treated with metastatic breast cancera. San Antonio Breast Cancer Symposium. 2008:#6073.

  21. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334–56.

    CAS  PubMed  Google Scholar 

  22. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90(18):1346–60.

    Article  CAS  PubMed  Google Scholar 

  23. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90(18):1361–70.

    Article  CAS  PubMed  Google Scholar 

  24. Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol. 2008;26(31):5027–35.

    Article  CAS  PubMed  Google Scholar 

  25. Dhesy-Thind B, Pritchard KI, Messersmith H, O’Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat. 2008;109(2):209–29.

    Article  CAS  PubMed  Google Scholar 

  26. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  27. O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101(9):644–50.

    Article  PubMed  CAS  Google Scholar 

  28. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) withdoxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94 Suppl 1 (Abstract 1).

  29. http://www.clinicaltrials.gov/ct2/show/NCT00689156.

  30. http://www.cancer.gov/clinicaltrials/NSABP-B-36.

  31. http://www.clinicaltrials.gov/ct2/show/study/NCT00801411.

  32. Di Leo A, Isola J, Piette F, Ejlersten B, Pritchard KI, Bartlett JMS, et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. In: 31st San Antonio Breast Cancer Symposium 2008:#705.

  33. Rouzier R, Rajan P, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci. 2005;102:8315–20.

    Article  CAS  PubMed  Google Scholar 

  34. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785(2):96–132.

    CAS  PubMed  Google Scholar 

  35. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 2006;97(9):813–20.

    Article  CAS  PubMed  Google Scholar 

  36. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 2005;23(3):422–31.

    Article  CAS  PubMed  Google Scholar 

  37. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362(9381):362–9.

    Article  CAS  PubMed  Google Scholar 

  38. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2006;99(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  39. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 2008;14(9):939–48.

    Article  CAS  PubMed  Google Scholar 

  40. Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M, et al. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol. 2009;34(2):361–70.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported in part by a Grant-in-aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control.

Author information

Authors and Affiliations

  1. Division of Breast Surgery, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo, 104-0045, Japan

    Sadako Akashi-Tanaka

Authors
  1. Sadako Akashi-Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sadako Akashi-Tanaka.

About this article

Cite this article

Akashi-Tanaka, S. Predicting responses to chemotherapy in breast cancer: from bench to bedside. Breast Cancer 17, 92–96 (2010). https://doi.org/10.1007/s12282-009-0166-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-009-0166-0

Keywords

Search

Navigation